CD19 and acute lymphoblastic leukemia: Two FDA-approved CAR-T-cell therapies targeting the CD19 molecule are available: the tisagenlecleucel (3–5) for adult B-cell acute lymphoblastic leukemia (B-ALL) and the axicabtagene ciloleucel for large B-cell non-Hodgkin lymphoma (6, 7).